Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer
Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.
Related Articles
FDA Grants Orphan Drug Designation to ELC-100 in Pancreatic NETs
Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we…
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
PURPOSEMelanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.METHODSWe assessed…
The importance of shared decision making | Biomarker-driven management of NSCLC
Alexander Drilon and Alex Miles discuss the importance of shared decision making throughout the course of an NSCLC patient’s treatment.
Call for Papers | Cancer Research | American Association for Cancer Research
Call for Papers | Cancer Research | American Association for Cancer Research .aacrcontent ul {list-style-image: url(‘/ImageLibrary/CR/icons/cr_bullet.png’);} .banner{ display: block; width: 100% margin: -20px; } .banner-sm{…
Summer Internship Program (SIP)
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…